Ted Bosworth is a medical journalist at Medscape. With over 40 years of experience, he has focused on medicine and healthcare, particularly in medical specialties such as surgery. His work has been featured in MediQuality, MDEdge, Knowledia, and Medscape, showcasing his extensive knowledge and coverage of the medical field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ted Bosworth's articles predominantly focus on healthcare and pharmaceutical topics, particularly in pediatric healthcare. He shows a strong preference for citing data to support his coverage. Therefore, when reaching out to him, consider providing access to relevant and credible data that can enhance the insights presented.
Given Ted's focus on pediatric healthcare and adherence to treatment among children, he may be interested in receiving pitches related to innovative treatments or medications specifically tailored for young patients. Additionally, considering his interest in scientific themes, he might appreciate expert opinions from researchers or clinicians who have conducted studies supporting new approaches or medications for pediatric diseases.
While geographic focus is not specified, it would be beneficial to provide information that has global relevance as Ted does not seem limited by specific regions in his coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ted Bosworth
November 06, 2025 SAN FRANCISCO — After 7 years, transcatheter aortic valve replacement (TAVR) remains equivalent to surgery with respect
By: Ted Bosworth
November 09, 2025 NEW ORLEANS — The first global randomized trial of the PCSK9 inhibitor evolocumab for the prevention of a primary major
December 03, 2025 NEW YORK — If not doing so already, dermatologists should participate, if not lead the care of cutaneous lupus
By: Ted Bosworth
December 30, 2025 NEW YORK — Potential upcoming approvals of JAK inhibitors for hidradenitis suppurativa (HS) and vitiligo suggest these
By: Ted Bosworth
Risk by FFR is continuous variable September 23, 2022 | Cardiology News FROM TCT 2022
August 28, 2023 | FROM ESC CONGRESS 2023 When added to guideline-directed therapies for heart failure with reduced ejection
By: Ted Bosworth
April 03, 2026 NEW ORLEANS — A balloon angioplasty device coated with sirolimus yielded significant reductions in major adverse events, including
By: Ted Bosworth
April 16, 2026 NEW ORLEANS — Intravascular ultrasound (IVUS) is already guideline recommended for complex percutaneous coronary
June 02, 2026 CHARLOTTE — The investigational oral Bruton tyrosine kinase inhibitor (BTKi) fenebrutinib significantly outperformed teriflunomide
June 15, 2026 DENVER — Nontraditional therapies are increasingly being subjected to clinical testing, providing clinicians in dermatology with an opportunity to counsel patients with some degree of objective information.
